Distribution of [11C]-JNJ-42491293 in the marmoset brain: a positron emission tomography study
- PMID: 36928556
- DOI: 10.1007/s00210-023-02458-w
Distribution of [11C]-JNJ-42491293 in the marmoset brain: a positron emission tomography study
Abstract
JNJ-42491293 is a metabotropic glutamate 2 (mGlu2) positive allosteric modulator (PAM) that was radiolabelled with [11C]- to serve as a positron emission tomography (PET) ligand. Indeed, in vitro, the molecule displays high selectivity at mGlu2 receptors. However, PET experiments performed in rats, macaques and humans, have suggested that [11C]-JNJ-42491293 could interact with an unidentified, non-mGlu2 receptor binding site. The brain distribution of [11C]-JNJ-42491293 has not been determined in the brain of the common marmoset, a small non-human primate increasingly used in neuroscience research. Here, we investigated the distribution of [11C]-JNJ-42491293 in the marmoset brain. Three marmosets underwent brain magnetic resonance imaging (MRI) and 90-min dynamic PET scans with [11C]-JNJ-42491293 in combination with vehicle or the mGlu2 PAM AZD8529 (0.1, 1 and 10 mg/kg). In the scans in which [11C]-JNJ-42491293 was co-administered with vehicle, the brain areas with the highest standardised uptake values (SUVs) were the midbrain, cerebellum and thalamus, while the lowest SUVs were found in the pons. The addition of AZD8529 (0.1, 1 and 10 mg/kg) to [11C]-JNJ-42491293 did not modify the SUVs obtained with [11C]-JNJ-42491293 alone, and ex vivo blocking autoradiography with PAM AZD8529 (10, 100, 300 µM) on marmoset brain sections showed increased signals in the blocking conditions compared to vehicle, suggesting that no competition occurred between the 2 ligands. The results we obtained here do not suggest that [11C]-JNJ-42491293 interacts selectively, or even at all, with mGlu2 receptors in the marmoset, in agreement with findings previously reported in macaque and human.
Keywords: AZD8529; Marmoset; PET; Positive allosteric modulator; [11C]-JNJ-42491293; mGlu2 receptor.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Andres JI, Alcazar J, Cid JM, De Angelis M, Iturrino L, Langlois X, Lavreysen H, Trabanco AA, Celen S, Bormans G (2012) Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging. J Med Chem 55(20):8685–8699. https://doi.org/10.1021/jm300912k - DOI - PubMed
-
- Campanelli F, Natale G, Marino G, Ghiglieri V, Calabresi P (2022) Striatal glutamatergic hyperactivity in Parkinson’s disease. Neurobiol Dis 168:105697. https://doi.org/10.1016/j.nbd.2022.105697 - DOI - PubMed
-
- Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, Linares ML, Garcia A, Andres JI, Macdonald GJ, Oehlrich D, Lavreysen H, Megens A, Ahnaou A, Drinkenburg W, Mackie C, Pype S, Gallacher D, Trabanco AA (2012) Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J Med Chem 55(20):8770–8789. https://doi.org/10.1021/jm3010724 - DOI - PubMed
-
- Cid JM, Trabanco AA, Lavreysen H (2015) Metabotropic glutamate receptor 2 activators. In: Celanire S, Poli S (eds) Small molecule therapeutics for schizophrenia, vol 13. Springer, Switzerland, pp 101–142 - DOI
-
- Dienel GA (2019) Brain Glucose Metabolism: Integration of Energetics with Function. Physiol Rev 99(1):949–1045. https://doi.org/10.1152/physrev.00062.2017 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
